Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
2.960
0.00 (0.00%)
At close: Oct 2, 2026, 4:00 PM EDT
3.180
+0.220 (7.43%)
After-hours: Oct 2, 2026, 7:50 PM EDT
Ernexa Therapeutics Employees
As of December 31, 2025, Ernexa Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,753,429
Market Cap
4.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% | 5 | 2 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 6 | 0 |
| Dec 31, 2023 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2022 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2021 | 10 | 0 | - | 10 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| NuCana | 12 |
| Processa Pharmaceuticals | 12 |
| Dermata Therapeutics | 9 |
| Lexaria Bioscience | 7 |
| Kairos Pharma | 4 |
| GRI Bio | 4 |
| 60 Degrees Pharmaceuticals | 3 |
ERNA News
- 2 days ago - Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic - GlobeNewsWire
- 3 days ago - Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101 - TheFly
- 3 days ago - Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - GlobeNewsWire
- 4 days ago - Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting - TheFly
- 4 days ago - Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy - GlobeNewsWire
- 16 days ago - Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D. - GlobeNewsWire
- 18 days ago - Ernexa reports preliminary results for ERNA-201, to focus resources on ERNA-101 - TheFly
- 18 days ago - Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing - GlobeNewsWire